Last updated on October 2018

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Brief description of study

This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

Clinical Study Identifier: NCT02483312

Contact Investigators or Research Sites near you

Start Over

Mark Minden, M.D.

Princess Margaret Centre Centre
Toronto, ON Canada
  Connect »